These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26895179)

  • 1. Pharmacological Therapy of Bronchial Asthma: The Role of Biologicals.
    Heck S; Nguyen J; Le DD; Bals R; Dinh QT
    Int Arch Allergy Immunol; 2015; 168(4):241-52. PubMed ID: 26895179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biologicals in the Treatment of Bronchial Asthma].
    Haasler I; Taube C
    Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
    Barnes PJ
    J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy.
    Huang YC; Weng CM; Lee MJ; Lin SM; Wang CH; Kuo HP
    Clin Exp Allergy; 2019 Jan; 49(1):44-53. PubMed ID: 30107059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the current role of biologics in the management of patients with severe refractory asthma?
    Draikiwicz S; Oppenheimer J
    Ann Allergy Asthma Immunol; 2016 May; 116(5):383-7. PubMed ID: 27153737
    [No Abstract]   [Full Text] [Related]  

  • 11. Pediatric use of omalizumab for allergic asthma.
    Pajno GB; Castagnoli R; Arasi S; Licari A; Caminiti L; Marseglia GL
    Expert Opin Biol Ther; 2020 Jul; 20(7):695-703. PubMed ID: 32241196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics in severe asthma.
    Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
    Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
    Kupryś-Lipińska I; Molińska K; Kuna P
    Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
    Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
    Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.
    Samitas K; Delimpoura V; Zervas E; Gaga M
    Eur Respir Rev; 2015 Dec; 24(138):594-601. PubMed ID: 26621973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of biologics for the treatment of asthma.
    Pelaia G; Vatrella A; Maselli R
    Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
    Ohta K; Nagase H; Suzukawa M; Ohta S
    Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel monoclonal treatments in severe asthma.
    Meteran H; Meteran H; Porsbjerg C; Backer V
    J Asthma; 2017 Dec; 54(10):991-1011. PubMed ID: 28287273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.